| Patent application number | Description | Published |
|---|
| 20110236594 | In-Situ Deposition of Film Stacks - Methods and hardware for depositing film stacks in a process tool in-situ (i.e., without a vacuum break or air exposure) are described. In one example, a method for depositing, on a substrate, a film stack including films of different compositions in-situ in a process station using a plasma is described, the method including, in a first plasma-activated film deposition phase, depositing a first layer of film having a first film composition on the substrate; in a second plasma-activated deposition phase, depositing a second layer of film having a second film composition on the first layer of film; and sustaining the plasma while transitioning a composition of the plasma from the first plasma-activated film deposition phase to the second plasma-activated film deposition phase. | 09-29-2011 |
| 20110236600 | Smooth Silicon-Containing Films - Methods and hardware for depositing ultra-smooth silicon-containing films and film stacks are described. In one example, an embodiment of a method for forming a silicon-containing film on a substrate in a plasma-enhanced chemical vapor deposition apparatus is disclosed, the method including supplying a silicon-containing reactant to the plasma-enhanced chemical vapor deposition apparatus; supplying a co-reactant to the plasma-enhanced chemical vapor deposition apparatus; supplying a capacitively-coupled plasma to a process station of the plasma-enhanced chemical vapor deposition apparatus, the plasma including silicon radicals generated from the silicon-containing reactant and co-reactant radicals generated from the co-reactant; and depositing the silicon-containing film on the substrate, the silicon-containing film having a refractive index of between 1.4 and 2.1, the silicon-containing film further having an absolute roughness of less than or equal to 4.5 Å as measured on a silicon substrate. | 09-29-2011 |
| 20130157466 | SILICON NITRIDE FILMS FOR SEMICONDUCTOR DEVICE APPLICATIONS - The embodiments herein relate to plasma-enhanced chemical vapor deposition methods and apparatus for depositing silicon nitride on a substrate. The disclosed methods provide silicon nitride films having wet etch rates (e.g., in dilute hydrofluoric acid or hot phosphoric acid) suitable for certain applications such as vertical memory devices. Further, the methods provide silicon nitride films having defined levels of internal stress suitable for the applications in question. These silicon nitride film characteristics can be set or tuned by controlling, for example, the composition and flow rates of the precursors, as well as the RF power supplied to the plasma and the pressure in the reactor. In certain embodiments, a boron-containing precursor is added. | 06-20-2013 |
| 20130171834 | IN-SITU DEPOSITION OF FILM STACKS - Disclosed herein are methods of forming a film stack which may include the plasma accelerated deposition of a silicon nitride film formed from the reaction of nitrogen containing precursor with silicon containing precursor, the plasma accelerated substantial elimination of silicon containing precursor from the processing chamber, the plasma accelerated deposition of a silicon oxide film atop the silicon nitride film formed from the reaction of silicon containing precursor with oxidant, and the plasma accelerated substantial elimination of oxidant from the processing chamber. Also disclosed herein are process station apparatuses for forming a film stack of silicon nitride and silicon oxide films which may include a processing chamber, one or more gas delivery lines, one or more RF generators, and a system controller having machine-readable media with instructions for operating the one or more gas delivery lines, and the one or more RF generators. | 07-04-2013 |
| 20130267081 | POST-DEPOSITION SOFT ANNEALING - The methods and apparatus disclosed herein concern a process that may be referred to as a “soft anneal.” A soft anneal provides various benefits. Fundamentally, it reduces the internal stress in one or more silicon layers of a work piece. Typically, though not necessarily, the internal stress is a compressive stress. A particularly beneficial application of a soft anneal is in reduction of internal stress in a stack containing two or more layers of silicon. Often, the internal stress of a layer or group of layers in a stack is manifest as wafer bow. The soft anneal process can be used to reduce compressive bow in stacks containing silicon. The soft anneal process may be performed without causing the silicon in the stack to become activated. | 10-10-2013 |
| 20140357064 | TENSILE STRESSED DOPED AMORPHOUS SILICON - The method and apparatus disclosed herein relate to preparing a stack structure for an electronic device on a semiconductor substrate. A particularly beneficial application of the method is in reduction of internal stress in a stack containing multiple layers of silicon. Typically, though not necessarily, the internal stress is a compressive stress, which often manifests as wafer bow. In some embodiments, the method reduces the internal stress of a work piece by depositing phosphorus doped silicon layers having low internal compressive stress or even tensile stress. The method and apparatus disclosed herein can be used to reduce compressive bow in stacks containing silicon. | 12-04-2014 |
| 20150013607 | IN-SITU DEPOSITION OF FILM STACKS - An apparatus for depositing film stacks in-situ (i.e., without a vacuum break or air exposure) are described. In one example, a plasma-enhanced chemical vapor deposition apparatus configured to deposit a plurality of film layers on a substrate without exposing the substrate to a vacuum break between film deposition phases, is provided. The apparatus includes a process chamber, a plasma source and a controller configured to control the plasma source to generate reactant radicals using a particular reactant gas mixture during the particular deposition phase, and sustain the plasma during a transition from the particular reactant gas mixture supplied during the particular deposition phase to a different reactant gas mixture supplied during a different deposition phase. | 01-15-2015 |
| Patent application number | Description | Published |
|---|
| 20100041736 | Isolated MCPIP and Methods of Use - A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed. | 02-18-2010 |
| 20110002981 | MCPIP Protection Against Cardiac Dysfunction - Disclosed herein are methods and compositions of treating a patient at risk of experiencing sepsis induced cardiac dysfunction. In exemplary examples, the method involves elevating MCPIP levels in a patient in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP). | 01-06-2011 |
| 20130295076 | MCPIP AS WOUND THERAPY - Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP). | 11-07-2013 |
| 20140341877 | MCPIP AS WOUND THERAPY - Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP). | 11-20-2014 |
| 20140341914 | ISOLATED MCPIP AND METHODS OF USE - A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed. | 11-20-2014 |
| Patent application number | Description | Published |
|---|
| 20090213206 | Aggregation of Video Receiving Capabilities - Video receiving capabilities of participants and source capabilities are compared and conference capabilities for providing different resolutions, frame rates, bit rate, and number of streams are determined by maintaining a conference receiving capability list updated as number and capability of participants' changes. Preferred receiving capabilities of participants are also taken into account in determining conference characteristics based on comparison with allowed capabilities. | 08-27-2009 |
| 20090231415 | Multiple Video Stream Capability Negotiation - Video send and receive capabilities of participants are determined by the respective machines determining available combinations, as well as preferences for the receivers. Receiver capabilities are forwarded to the source for computation of negotiated video capabilities through a logic intersection of the determined capabilities based on desired number of streams and resolutions. If a resolution of a send capability exists within the receive capability, the highest frame and/or bit rate may be selected for transmission. | 09-17-2009 |
| 20120154516 | AGGREGATION OF VIDEO RECEIVING CAPABILITIES - Video receiving capabilities of participants and source capabilities are compared and conference capabilities for providing different resolutions, frame rates, bit rate, and number of streams are determined by maintaining a conference receiving capability list updated as number and capability of participants' changes. Preferred receiving capabilities of participants are also taken into account in determining conference characteristics based on comparison with allowed capabilities. | 06-21-2012 |
| 20120176469 | MULTIPLE VIDEO STREAM CAPABILITY NEGOTIATION - Video send and receive capabilities of participants are determined by the respective machines determining available combinations, as well as preferences for the receivers. Receiver capabilities are forwarded to the source for computation of negotiated video capabilities through a logic intersection of the determined capabilities based on desired number of streams and resolutions. If a resolution of a send capability exists within the receive capability, the highest frame and/or bit rate may be selected for transmission. | 07-12-2012 |
| Patent application number | Description | Published |
|---|
| 20120249128 | MAGNETIC SENSOR SYSTEM - A linear sensor system includes a first field sensor displaced linearly from a second field sensor. A member having high magnetic permeability is disposed between the first field sensor and the second field sensor. The member is optimized in shape and material to completely remove any redirection or interference of the magnetic flux in the field sensors. A torque transmitting device incorporating the linear sensor system is also disclosed. | 10-04-2012 |
| 20120286613 | ASYMMETRIC STATOR TEETH IN AN ELECTRIC MOTOR - A permanent magnet motor includes a permanent magnet rotor, a stator surrounding the rotor having a plurality of teeth radially inwardly oriented toward a longitudinal axis of the stator wherein each tooth has a tooth length and a tooth tip surface geometry. An asymmetric air gap is defined by variations in the tooth lengths and tooth tip surface geometries. | 11-15-2012 |
| 20120293105 | ROTOR SLOT ASYMMETRY IN AN ELECTRIC MOTOR - An electric motor includes a stator configured to receive electrical energy and generate an electromagnetic field in accordance with the electrical energy received. A rotor is in electromagnetic communication with the stator and is configured to rotate in accordance with the electromagnetic field generated by the stator. The rotor includes a plurality of poles including a first set of poles and a second set of poles. The first set of poles defines a first slot and the second set of poles defines a second slot that has a different configuration than the first slot to reduce a torque ripple effect. The electric motor may be used in a system having a power source configured to output direct current energy and an inverter configured to convert direct current energy to alternating current energy. | 11-22-2012 |
| 20130020896 | ROTOR FOR A PERMANENT MAGNET ELECTRIC MACHINE - A rotor for a permanent magnet electric machine includes an axis of rotation, an outer surface, and a cross-section orthogonal to the axis of rotation with a non-circular contour of the outer surface defined by a plurality of radii angularly distributed around the axis of rotation. | 01-24-2013 |
| 20130069470 | INTERIOR PERMANENT MAGNET MACHINE WITH RADIALLY ASYMMETRIC MAGNET CONFIGURATION - An interior permanent magnet machine is provided with a rotor that includes a plurality of slots and at least one barrier defined by the plurality of slots. A plurality of first and second magnets are disposed within the barrier. The rotor is configured such that at least one of the first magnets is located at a different radial distance from the center of the rotor relative to at least one of the second magnets. The rotor may be configured to produce an averaging effect similar to that achieved through traditional skewing of rotor magnets. The rotor includes a plurality of poles defined by respective pole axes in the rotor and may be configured to reflect radial asymmetry between poles (pole-to-pole) and/or radial asymmetry within a pole. | 03-21-2013 |
| 20130147309 | ROTOR GEOMETRY FOR REDUCTION OF TORQUE RIPPLE IN A WOUND FIELD MACHINE - An electric machine is provided with a rotor configured to be rotatable within a stator. A first and second tooth are disposed circumferentially along an outer perimeter of the rotor and at least partially define a first slot. The first and the second tooth define a respective first and second outer edge extending between a respective tooth base and a respective tooth tip. An arc radius from the origin to the outer perimeter of the rotor varies along the first outer edge of the first tooth, thereby creating a first non-uniform gap between the rotor and the stator. The arc radius from the origin to the outer perimeter of the rotor varies along the second outer edge of the second tooth, thereby creating a second non-uniform gap between the rotor and the stator. The rotor geometry is configured to reduce torque ripple without skewing either the rotor or the stator. | 06-13-2013 |
| 20130154622 | MAGNETIC LINEAR POSITION SENSOR - A magnetic linear position sensor includes an array of N number of magnets. The array of magnets is distributed along a line to form a magnetic field relay along the line. The sizes and positions of the magnets in the array of magnets are symmetric along the line, and the size of the magnets decreases from the sides of the array of magnets towards the center of the array of magnets. The magnetic linear position sensor further includes a magnetic field sensor spaced apart and positioned above the array of magnets. The magnetic field sensor moves back and forth over the array of magnets to sense the magnetic field of the array of magnets. | 06-20-2013 |
| 20130270952 | AXIALLY ASYMMETRIC PERMANENT MAGNET MACHINE - A permanent magnet machine is provided with a rotor positioned at least partially within a stator. The rotor includes first and second ring segments oriented axially around a central axis. The rotor defines first and second configurations in the first and second ring segments, respectively. The first configuration is sufficiently different from the second configuration such that torque ripple may be minimized. A first layer of slots, defining a slot outer edge, may be formed in the rotor. In one embodiment, a stator-to-slot gap varies between the first and second ring segments. In another embodiment, a stator-rotor gap varies between the first and second ring segments. In another embodiment, a bridge thickness varies between the first and second ring segments. Thus the rotor exhibits axial asymmetry. | 10-17-2013 |
| 20140217848 | INTERIOR PERMANENT MAGNET MACHINE - An interior permanent magnet machine includes a stator including a plurality of electrical conductors. The interior permanent magnet machine further includes a rotor concentrically disposed in relation to the stator. The rotor is configured to rotate relative to the stator about a rotational axis and includes a plurality of polar pieces arranged annularly about the rotational axis. At least one of the polar pieces includes a magnetic layer configured to magnetically interact with the electrical conductors. The magnetic layer has a substantially conic section shape. | 08-07-2014 |
| Patent application number | Description | Published |
|---|
| 20100169997 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 07-01-2010 |
| 20110078823 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 03-31-2011 |
| 20110252506 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 10-13-2011 |
| 20120102594 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 04-26-2012 |
| 20130205442 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 08-08-2013 |
| Patent application number | Description | Published |
|---|
| 20110045575 | MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL AND RELATED METHODS - The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO. | 02-24-2011 |
| 20110129899 | MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL, 4-HYDROXYBUTANAL, 4-HYDROXYBUTYRYL-COA, PUTRESCINE AND RELATED COMPOUNDS, AND METHODS RELATED THERETO - The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine. | 06-02-2011 |
| 20110217742 | MICROORGANISMS AND METHODS FOR THE COPRODUCTION 1,4-BUTANEDIOL AND GAMMA-BUTYROLACTONE - The invention provides non-naturally occurring microbial organisms comprising 1,4-butanediol (14-BDO) and gamma-butyrolactone (GBL) pathways comprising at least one exogenous nucleic acid encoding a 14-BDO and GBL pathway enzyme expressed in a sufficient amount to produce 14-BDO and GBL. The invention additionally provides methods of using such microbial organisms to produce 14-BDO and GBL. | 09-08-2011 |
| 20110229946 | MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL, 4-HYDROXYBUTANAL, 4-HYDROXYBUTYRYL-COA, PUTRESCINE AND RELATED COMPOUNDS, AND METHODS RELATED THERETO - The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine. | 09-22-2011 |
| 20120225463 | MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL AND RELATED METHODS - The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO. | 09-06-2012 |
| 20130029381 | MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL, 4-HYDROXYBUTANAL, 4-HYDROXYBUTYRYL-COA, PUTRESCINE AND RELATED COMPOUNDS, AND METHODS RELATED THERETO - The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine. | 01-31-2013 |
| 20130189751 | MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL, 4-HYDROXYBUTANAL, 4-HYDROXYBUTYRYL-COA, PUTRESCINE AND RELATED COMPOUNDS, AND METHODS RELATED THERETO - The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine. | 07-25-2013 |
| 20130196397 | COMPOSITIONS AND METHODS FOR THE BIOSYNTHESIS OF 1,4-BUTANEDIOL AND ITS PRECURSORS - The invention provides a non-naturally occurring microbial biocatalyst including a microbial organism having a 4-hydroxybutanoic acid (4-HB) biosynthetic pathway having at least one exogenous nucleic acid encoding 4-hydroxybutanoate dehydrogenase, succinyl-CoA synthetase, CoA-dependent succinic semialdehyde dehydrogenase, or α-ketoglutarate decarboxylase, wherein the exogenous nucleic acid is expressed in sufficient amounts to produce monomeric 4-hydroxybutanoic acid (4-HB). Also provided is a non-naturally occurring microbial biocatalyst including a microbial organism having 4-hydroxybutanoic acid (4-HB) and 1,4-butanediol (BDO) biosynthetic pathways, the pathways include at least one exogenous nucleic acid encoding 4-hydroxybutanoate dehydrogenase, succinyl-CoA synthetase, CoA-dependent succinic semialdehyde dehydrogenase, 4-hydroxybutyrate:CoA transferase, 4-butyrate kinase, phosphotransbutyrylase, α-ketoglutarate decarboxylase, aldehyde dehydrogenase, alcohol dehydrogenase or an aldehyde/alcohol dehydrogenase, wherein the exogenous nucleic acid is expressed in sufficient amounts to produce 1,4-butanediol (BDO). Additionally provided are methods for the production of 4-HB and BDO. | 08-01-2013 |
| 20140162327 | MICROORGANISMS AND METHODS FOR THE COPRODUCTION 1,4-BUTANEDIOL AND GAMMA-BUTYROLACTONE - The invention provides non-naturally occurring microbial organisms comprising 1,4-butanediol (14-BDO) and gamma-butyrolactone (GBL) pathways comprising at least one exogenous nucleic acid encoding a 14-BDO and GBL pathway enzyme expressed in a sufficient amount to produce 14-BDO and GBL. The invention additionally provides methods of using such microbial organisms to produce 14-BDO and GBL. | 06-12-2014 |
| Patent application number | Description | Published |
|---|
| 20100305288 | Fused Thiophenes, Articles, and Methods Thereof - Fused thiophene (FT) compounds, FT polymers, FT containing articles, and methods for making and using the FT compounds and polymers thereof of the formulas, as defined herein. | 12-02-2010 |
| 20110166307 | FUSED THIOPHENES, ARTICLES, AND METHODS THEREOF - Fused thiophene (FT) compounds, FT polymers, FT containing articles, and methods for making and using the FT compounds and polymers thereof of the formulas, as defined herein. | 07-07-2011 |
| 20110288306 | METHODS OF MAKING FUSED THIOPHENES - β″-di-R-substituted fused thiophene (DCXFT4) compounds, and a method for making a compound of the formula (V): | 11-24-2011 |
| 20110291054 | POLYMERIC FUSED THIOPHENE SEMICONDUCTOR FORMULATION - A formulation including:
| 12-01-2011 |
| 20120022116 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX - Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III): | 01-26-2012 |
| 20120035375 | DI-TIN FUSED THIOPHENE COMPOUNDS AND POLYMERS AND METHODS OF MAKING - Di-tin fused thiophene (FT) compounds, FT polymers, such as of the formula -{-(FTx)-(Ar) | 02-09-2012 |
| 20120220748 | FIVE-RING FUSED HETEROAROMATIC COMPOUNDS AND CONJUGATED POLYMERS THEREOF - Compounds having a core comprised of an aromatic ring and at least two annulated beta-substituted fused thiophene ring systems of the general formula: | 08-30-2012 |
| 20120295965 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER - Disclosed are compositions and methods related to identification of modulators of EGFR and VEGFR. | 11-22-2012 |
| 20120329865 | MOLECULES RELATED hERG ION CHANNELS AND THE USE THEREOF - Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R | 12-27-2012 |
| 20130085256 | FUSED THIOPHENES, METHODS OF MAKING FUSED THIOPHENES, AND USES THEREOF - Described herein are compositions including heterocyclic organic compounds based on fused thiophene compounds, polymers based on fused thiophene compounds, and methods for making the monomers and polymer along with uses in thin film-based and other devices. | 04-04-2013 |
| 20130109821 | CONJUGATED FUSED THIOPHENES, METHODS OF MAKING CONJUGATED FUSED THIOPHENES, AND USES THEREOF | 05-02-2013 |
| 20130178599 | FIVE-RING FUSED HETEROAROMATIC COMPOUNDS AND CONJUGATED POLYMERS THEREOF - Compounds having a core comprised of an aromatic ring and at least two annulated beta-substituted fused thiophene ring systems of the general formula: | 07-11-2013 |
| 20130302003 | PRIMARY OPTICAL FIBER COATING COMPOSITION CONTAINING NON-RADIATION CURABLE COMPONENT - A radiation curable composition is disclosed that includes a curable cross-linker essentially free of urethane and urea functional groups, a curable diluent, and a non-radiation curable component comprising (thio)urethane and/or urea groups. Coated optical fibers having a primary coating formed from this radiation curable composition, as well as optical fiber ribbons that contain the coated optical fibers are disclosed. Methods of making the optical fibers and ribbons are also disclosed. | 11-14-2013 |
| 20140341521 | LOW COST, FAST CURING OPTICAL FIBER COATINGS - A low cost composition that cures rapidly and which is suitable for coating an optical fiber comprises at least one ethylenically unsaturated monomer; at least one photoinitiator; and at least one non-radiation-curable polar polymer having pendent groups that facilitate low energy chemical bonding, hydrogen bonding, dipolar interactions or other interactions with radical compounds formed during polymerization of the monomer. The non-radiation-curable polar polymer(s) are inexpensive and reduce and/or eliminate the need for expensive urethane acrylate oligomers, without sacrificing properties, and while achieving rapid cure speeds. | 11-20-2014 |
| 20140341524 | OPTICAL FIBER COATING COMPOSITIONS WITH NON-CURABLE REINFORCING AGENTS - A coating composition including a reinforcing agent. The coating composition may include one or more radiation-curable monofunctional monomers, one or more radiation-curable multifunctional monomers or oligomers, a photoinitiator, and a reinforcing agent. The monofunctional monomers, multifunctional monomers, and multifunctional oligomers may include acrylate groups. The reinforcing agent may be an acrylic co-polymer that includes two or more repeat units. At least one of the repeat units includes chemical groups that enable self-association of the acrylic co-polymer. Self-association of the acrylic co-polymer may improve the tensile strength of coatings formed from the coating compositions. | 11-20-2014 |
| 20140357889 | SYNTHESIS OF POLYFUNCTIONAL POLYOL ACRYLATES - A method of synthesizing urethane-free polyfunctional acrylate compounds. The method includes reaction of a polyol with acrylic acid in the presence of an inhibitor. A catalyst may also be present. The catalyst may be an acid and the inhibitor may be a substituted phenol compound. Excess acid may be removed by adding a salt and excess water may be removed by adding a drying agent. The reaction converts alcohol groups of the polyol to acrylate groups to provide a radiation-curable polyfunctional acrylate compound. The reaction is applicable to polyols generally and provides a scalable high yield process for forming urethane-free polyfunctional acrylates over a wide range of molecular weights. Coatings made from the acrylate products exhibit modulus and tensile strength characteristics favorable for primary fiber coatings. | 12-04-2014 |
| 20150045560 | NOVEL FUSED NAPHTHALENE CYCLOHETERO RING COMPOUNDS, AND METHODS AND USES THEREOF - Described herein are heterocyclic organic compounds of following formulae: More specifically, described herein are fused heterocyclic naphthalene compounds, polymers based on fused heterocyclic naphthalene compounds, methods for making these compounds, and uses thereof. The compounds described have improved polymerization and stability properties that allow for improved material processibility for use as organic semiconductors (OSCs). | 02-12-2015 |
| 20150057420 | BORON ESTER FUSED THIOPHENE MONOMERS - A compound of formula (I), formula (II), or a combination thereof, and salts thereof is described. | 02-26-2015 |
| 20150065722 | FUSED THIOPHENE DITIN MONOMERS - The disclosure relates to thiophene-based ditin compounds and methods of making and using such compounds. The disclosed compounds are novel structures having organotin groups on a conjugated aryl group spaced from and adjacent to a fused thiophene moiety. The formation of trialkyl tin groups spaced away from the fused thiophene moieties is advantageous in that it allows for novel polymerization via Stille coupling. | 03-05-2015 |
| Patent application number | Description | Published |
|---|
| 20110046398 | INTERMEDIATES IN THE SYNTHESIS ZEARALENONE MACROLIDE ANALOGS - Disclosed herein are methods and intermediates useful in the preparation of macrolides, e.g., compounds of formula (IV), wherein R | 02-24-2011 |
| 20110060151 | REAGENTS AND METHODS FOR THE BETA-KETO AMIDE SYNTHESIS OF A SYNTHETIC PRECURSOR TO IMMUNOLOGICAL ADJUVANT E6020 - This invention relates to the synthesis for a precursor of E6020, compound 26, via a β-keto amide alcohol intermediate, compound 22. The synthesis reacts compound 22 with compound 25 and the resultant intermediate is oxidized to produce compound 26, the precursor to E6020. Compounds 22 and 25, and their crystalline forms, represent separate embodiments of the invention. The invention also relates to compounds of formulas (3) and (4) and processes for their preparation. | 03-10-2011 |
| 20110237805 | INTERMEDIATES AND METHODS FOR MAKING ZEARALENONE MACROLIDE ANALOGS - Disclosed herein are methods and intermediates useful in the preparation of macrolides, e.g., compounds of formula (IV) wherein R | 09-29-2011 |
| 20130211103 | INTERMEDIATES AND METHODS FOR MAKING ZEARALENONE MACROLIDE ANALOGS - Disclosed herein are methods and intermediates useful in the preparation of macrolides, e.g., compounds of formula (IV) | 08-15-2013 |
| Patent application number | Description | Published |
|---|
| 20130304386 | RANDOM ESTIMATION IN POSITRON EMISSION TOMOGRAPHY WITH TANGENTIAL TIME-OF-FLIGHT MASK - A method of estimating random events in positron emission tomography list mode data, including obtaining time-of-flight (TOF) list mode count data that includes TOF information; converting the obtained TOF list mode count data into four-dimensional (4D) raw sinogram count data, without using the TOF information, wherein the 4D raw sinogram count data includes random count values; interpolating the 4D raw sinogram count data to generate 4D interpolated sinogram count data; low-pass filtering the 4D interpolated sinogram count data to remove noise; converting the low-pass filtered 4D interpolated sinogram count data into filtered 4D raw sinogram count data; and generating, by a processor, five-dimensional (5D) TOF raw sinogram count data from the filtered 4D raw sinogram count data by effectively applying a TOF mask filter to the filtered 4D raw sinogram count data. | 11-14-2013 |
| 20130308873 | APPARATUS AND METHOD FOR SMOOTHING RANDOM EVENT DATA OBTAINED FROM A POSITRON EMISSION TOMOGRAPHY SCANNER - A method and apparatus for smoothing random event data obtained from a Positron Emission Tomography (PET) scanner. The method includes obtaining initial random event data u(s, φ, t=0)=u | 11-21-2013 |
| 20130311142 | RANDOM COINCIDENCE REDUCTION IN POSITRON EMISSION TOMOGRAPHY USING TANGENTIAL TIME-OF-FLIGHT MASK - A method and apparatus for reducing random events in positron emission tomography (PET) list mode data, the method including the steps of obtaining, for a PET scanner having a given reconstruction field of view (FOV), time-of-flight (TOF) prompt list-mode count data that includes TOF information, the TOF prompt list-mode count data including a plurality of entries; and filtering the obtained prompt list-mode count data by removing those entries in the obtained prompt list-mode count data that represent emission points lying outside a tangential TOF mask to obtain filtered list-mode count data. | 11-21-2013 |
| 20140095106 | FIELD-OF-VIEW-DEPENDENT COINCIDENCE WINDOW FOR POSITRON EMISSION TOMOGRAPHY - A method and apparatus for determining a coincidence window for imaging a region of interest of an object using a Positron Emission Tomography (PET) scanner. The method includes determining a diameter of a transverse field of view (FOV) for imaging the region of interest of the object; and calculating the coincidence window based on the determined diameter, a ring diameter of the PET scanner, an axial length of the PET scanner, and a time-of-flight resolution of the PET scanner. | 04-03-2014 |
| Patent application number | Description | Published |
|---|
| 20080234340 | Synthesis and characterization of polymorph form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-YL)thiazol-4-YL)benzonitrile - A polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile and methods of preparing Form II are described. Also provided are methods of contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus including using polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile. | 09-25-2008 |
| 20080312306 | POLYMORPHS, SOLVATES, AND HYDRATE OF 5-(4'-FLUORO-2'-OXO-1',2'-DIHYDROSPIRO[CYCLOPROPANE-1,3'-INDOL]-5'-YL)-1-METHYL-1H-PYRROLE-2-CARBONITRILE - Novel polymorph Form II and III, solvate Forms I, II, III, and IV, and the hydrate of 5-(4′-fluoro-2′-oxo-1′,2′-dihydrospiro[cyclopropane-1,3′-indol]-5′-yl)-1-methyl-1H-pyrrole-2-carbonitrile are provided, as are methods for preparing the same. Pharmaceutical compositions and kits containing these novel polymorphs, solvates, and hydrate, and combinations thereof are further provided, as are methods of contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, hormone-dependent carcinomas; treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; or treating symptoms of premenstrual syndrome using one or more of these polymorphs, solvates, or hydrate. | 12-18-2008 |
| 20110281900 | Crystalline Pharmaceutical - New crystalline forms of lopinavir are disclosed. | 11-17-2011 |
| 20140303369 | Crystalline Pharmaceutical - New crystalline forms of lopinavir are disclosed. | 10-09-2014 |
